Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04101838 · ClinicalTrials.gov registry record · Phase 4
B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults
A Phase 4 study of Influenza, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04101838 is a Phase 4 study of Influenza that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 50 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04101838, a Phase 4 study of Influenza, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine how various FDA-approved seasonal influenza vaccine types, used in a manner consistent with their approved use, impact the characteristics of influenza specific antibodies in humans, and how these responses differ based on age and prior immunization history.
Conditions Studied
Interventions
- DRUG Fluzone
- DRUG Flucelvax
- DRUG Fluzone High-Dose
- DRUG Fluad
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2026-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04101838
The ClinicalTrials.gov registry entry for NCT04101838 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 4 interventions - of which Fluzone is the first listed.
NCT04101838 reports 1 study location spanning 1 distinct geographic area - top geographies include Alabama.
Frequently Asked Questions
What is clinical trial NCT04101838 about?
NCT04101838 is a clinical study titled "B Cell and Antibody Response to Seasonal Influenza Vaccines in Younger and Older Adults". This study will examine how various FDA-approved seasonal influenza vaccine types, used in a manner consistent with their approved use, impact the characteristics of influenza specific antibodies in humans, and how these responses differ based on age and prior immunization history.
What is the current status of trial NCT04101838?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2021-04-01. Estimated completion is 2026-05.
What conditions does trial NCT04101838 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT04101838?
The interventions under investigation include: Fluzone (DRUG), Flucelvax (DRUG), Fluzone High-Dose (DRUG), Fluad (DRUG).
Who is sponsoring clinical trial NCT04101838?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04101838 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study
RECRUITING · Phase 4
-
Bone Marrow and Peripheral Blood Immune Responses Study
RECRUITING · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine
COMPLETED · Phase 4
-
A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age
COMPLETED · Phase 4
-
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
COMPLETED · Phase 4
-
Study to Evaluate the Safety of 1 New 6:2 Influenza Virus Reassortant in Adults for the 2017-2018 Season
COMPLETED · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.